First Pharma CRM application for iPhone in the world

Fast, simple, functional and revolutionary! Sales Vision iTouch is comming soon on the market and it is about first Pharma CRM application that supports the work on iPhone globally. Lately there were rumors that were are preparing a new version of Sales Vision on iPhone - and it`s finally here! We are proudly announcing that our region has finally gotten a competive CRM application for iPhone.

PharmaBrand Summit 2010

21-23 June 2010, Le Méridien Beach Plaza, Monte-Carlo, Monaco

The PharmaBrand Europe Summit 2010 will bring together senior-level executives from Europe's largest organisations with a select and diversified group of leading edge Solution Providers. Do not miss this opportunity to network with your peers and form new alliances. Get a head start on your competition and start building relationships today.

Disease Modification in Rheumatoid Arthritis - Anti-TNFs defend first-line biologic position despite competition

Datamonitor forecasts that total sales for the seven major rheumatoid arthritis markets will grow from $7 billion in 2007 to over $12 billion in 2017. The sustained uptake of anti-TNFs combined with the launch of several new biologic products will drive growth in the short-and mid-term. However, biosimilar entry will cause a small contraction in market value at the end of the forecast period.

Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market

Drugs with new mechanisms, in particular Pfizer's oral JAK inhibitor CP-690,550 and Chugai/Roche's Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. Late-stage pipeline launches will be a major contributor to market growth from $7.4 billion in 2008 to $11.5 billion in 2018.

AstraZeneca deal lifts Rigel's arthritis drug out of development uncertainty

Having signed a license agreement with AstraZeneca, Rigel has boosted the prospects for R788, its RA drug. However, Phase III trials must address certain safety signals and reassure physicians of its efficacy in key patient populations. Prominent product differentiation will also be vital for the drug to compete with Pfizer's JAK inhibitor, which is set to reach the market two years ahead of it.

Lacerta BioCapital

Lacerta BioCapital, a member of Farmavita.Net, invests in sound, stable companies in promising Life Science segments with attractive futures (e.g., sustained positive cash flow; value increase potential of at least 20% p.a.; growth potential either organically or through acquisition; etc.). Our target companies have a sound customer base with a well balanced product portfolio. We aim to have a total investment budget of approximately €300 million (including credit capital), to be invested in around 10-15 Life Science companies.

Please contact us for introduction to Lacerta BioCapital. 

Pain Market Overview - Non-traditional analgesics and opioid reformulations to sustain sector growth

The mature pain market has experienced a turbulent 4-year period during which the estimated seven major market sales value has fallen from an all-time high in 2004 down to $24.29 billion in 2007. However, through the growing use of non-traditional analgesics and the emergence of a number of opioid reformulations, the market is set to consolidate in a new phase of growth and prosperity.

The Pain Management Market Outlook To 2014: Competitive landscape, pipeline analysis and growth opportunities

This report provides comprehensive coverage of major markets within the global pain management area, incorporating a epidemiological analysis of key neuropathic and nociceptive pain indications and the main factors impacting their prevalence. This report reviews the factors and underlying trends that are shaping the pain management market and identifies areas of potential growth.

Neuropathic Pain - Brighter future for pipeline drugs while current brands downgraded

Datamonitor forecasts the neuropathic pain market to more than double in value from 2008 to total $5.2 billion by 2018 across the seven major markets (US, Japan, and the 5EU [France, Germany, Italy, Spain and the UK]). Although the US will provide the greatest increase in value over this period, Japan and the 5EU markets will post double-digit compound annual growth rates.

New hope for Javelin's pain candidate but safety concerns remain

An external review of Phase III data for Javelin Pharmaceuticals' Ereska has found previously negative top-line results for its primary endpoint to be statistically significant. While the findings offer renewed hope for the company, ketamine's association with drug abuse and its well-documented hallucinatory effects represent key weaknesses in the market place, despite Ereska's proven efficacy.

3rd Annual Pharmaceutical Pricing & Reimbursement in Central & Eastern Europe

Budapest, Hungary, June 7th-8th, 2010

This event will present the most updated and original perspectives on communicating the cost-effectiveness of high valued drugs to key stakeholders in the former communist countries of Central and Eastern Europe (CEE EU members, The Balkans, Russia and the former Soviet states).

Transforming Drug Discovery

Press Release - 16 February 2010

Dr Chas Bountra, the Chairman of the marcus evans Discovery Summit 2010 shares his recommendations for drug discovery acceleration across Europe.

Drug discovery requires a lot of time, effort, brain power and money. At the moment a lot of that is being wasted as pharmaceutical companies often work secretly doing the same experiments with ridiculously low success rates. Dr Chas Bountra, Chief Scientist at the University of Oxford's Structural Genomics Consortium (SGC) is working towards transforming this status quo. The Chairman of the marcus evans Discovery Summit 2010, taking place in France, 22 - 24 March, has joined forces with scientists from across the world and is making all the SGC data publicly available, to reduce the duplication of experiments. Here he shares his vision of the drug discovery future and his ideas on accelerating the discovery process.

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Stakeholder Opinions: Back Pain - Gain competitive edge by targeting subpopulations

Back pain can restrict activity and quality of everyday life and in some cases is a potentially chronic and even crippling condition. Therefore, back pain exerts a large economic impact on society. Due to the high prevalence of back pain, Datamonitor believes that the condition represents a commercially attractive target to pharmaceutical companies with an interest in the pain market.

Pfizer's novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug's analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, Datamonitor expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy.

Medical Imaging - Global Displays and Post-Processing Software Market (2009 -2014)

Rising healthcare costs and the increasing demand for healthcare services have effected a significant transformation in the field of healthcare image management software over the last decade. Healthcare equipment vendors are now seeking to provide an integrated diagnostic model facilitating patient-centric, evidence-based healthcare. The major features of post-processing include workflow tasks such as image processing, image reconstruction, computer-aided detection, three-dimensional (3D) view generation, and quality control.

USA Information Exchange

Prague, April 27th, 2010

Arriello is pleased to announce the first information exchange meeting between key US representatives to take place in Prague, Czech Republic on April 27th, 2010. This conference is a chance to learn from US experts about the current US situation regarding REMS, OTC medicines and language.

US and European Ultrasound Systems Market: Increasing Demand to Drive Growth

GlobalData, the industry analysis specialists' new report, "US and European Ultrasound Systems Market: Increasing Demand to Drive Growth", finds that an aging population growth coupled with cost-effectiveness and advancements in technology are expected to drive growth in the US and Europe ultrasound systems market. The report highlights these factors as the key drivers for the US and Europe ultrasound systems market.